Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II carboplatin addition in neoadjuvant therapy for triple-negative and HER2-positive early breast cancer
2011-000553-23Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- May 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of carboplatin in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Pathological complete response ypT0 ypN0. Started May 2011; status: completed.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2011-000553-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000553-23.